MetaBiom
Microbiome & Chronic Diseases

Evidence Based Medicine
Sign in

Autoimmune Thyroid Disorders {40000523}

Record Keys


Definition:
Autoimmune Thyroid Disorders
Class:[  ]

Details


Other Terms:
ATD
Initialisation date:
2021-01-25

Meta Information


ICD:[  ]
Category:[  ]
MedDra ID:[  ]
MedDra Level:[  ]

Notes


- Hashimoto’s thyroiditis (HT) and Graves’ disease (GD) are the most prevalent forms of autoimmune thyroid disorders (ATD)

Shared Notes


  • [1.1
    - Firmictus/Bacteroidetes ratio is decreased in patients with ATD with no difference between GD & HT patients.
    - The relative abundance of beneficial bacteria associated with the gut barrier and anti‐inflammatory state; A.mucinophilia, Bifidobacterium, Lactobacillus, and F. prausnitzii, is decreased in ATD patients.
    - TRAb in GD patients and anti‐TPO in HT patients showe have a positive correlation with Bacteroidetes.


[Coverage other Diseases (Overlap > 0.25)]

DiseaseOverlapCommon increased OrganismCommon decreased Organism
Autoimmune Thyroid Disorders 1.0000 1 (100%) : Bifidobacteria 4 (100%) : Akkermansia muciniphila | Bifidobacterium | Faecalibacterium prausnitzii | Lactobacillus
Type 1 diabetes 0.5000 0 (0%) 4 (100%) : Akkermansia muciniphila | Bifidobacterium | Faecalibacterium prausnitzii | Lactobacillus
Crohn's disease 0.5000 0 (0%) 4 (100%) : Akkermansia muciniphila | Bifidobacterium | Faecalibacterium prausnitzii | Lactobacillus
Ulcerative Colitis 0.5000 0 (0%) 4 (100%) : Akkermansia muciniphila | Bifidobacterium | Faecalibacterium prausnitzii | Lactobacillus
Obesity 0.5000 0 (0%) 4 (100%) : Akkermansia muciniphila | Bifidobacterium | Faecalibacterium prausnitzii | Lactobacillus
Type 2 diabetes 0.3750 0 (0%) 3 (75%) : Akkermansia muciniphila | Bifidobacterium | Faecalibacterium prausnitzii
Autism 0.3750 0 (0%) 3 (75%) : Bifidobacterium | Faecalibacterium prausnitzii | Lactobacillus
Colorectal cancer 0.3750 0 (0%) 3 (75%) : Bifidobacterium | Faecalibacterium prausnitzii | Lactobacillus
Cystic fibrosis 0.3750 0 (0%) 3 (75%) : Akkermansia muciniphila | Bifidobacterium | Faecalibacterium prausnitzii
Celiac Disease 0.3750 0 (0%) 3 (75%) : Bifidobacterium | Faecalibacterium prausnitzii | Lactobacillus

[Coverage Factors (Overlap > 0.10)]

FactorOverlapCommon increased OrganismCommon decreased Organism
Consumption of Lactulose 0.5000 1 (100%) : Bifidobacteria 0 (0%)
Intake of heat-treated lactobacilli 0.5000 1 (100%) : Bifidobacteria 0 (0%)
Chemotherapy treatment 0.2500 0 (0%) 2 (50%) : Bifidobacterium | Faecalibacterium prausnitzii
Aging 0.1250 0 (0%) 1 (25%) : Bifidobacterium
Non-nutritive Sweeteners 0.1250 0 (0%) 1 (25%) : Akkermansia muciniphila
Keto diet 0.1250 0 (0%) 1 (25%) : Bifidobacterium
Oral administration of Metformin 0.1250 0 (0%) 1 (25%) : Lactobacillus
Sugar intake 0.1250 0 (0%) 1 (25%) : Lactobacillus
Low FODMAP diet 0.1250 0 (0%) 1 (25%) : Bifidobacterium
Exposure to Glyphosate 0.1250 0 (0%) 1 (25%) : Lactobacillus
High salt diet 0.1250 0 (0%) 1 (25%) : Lactobacillus
Maternal Antibiotic Exposure 0.1250 0 (0%) 1 (25%) : Bifidobacterium
Heat Stress 0.1250 0 (0%) 1 (25%) : Lactobacillus
Consumption of Iron sulfat 0.1250 0 (0%) 1 (25%) : Faecalibacterium prausnitzii
Grape powder consumption 0.1250 0 (0%) 1 (25%) : Bifidobacterium

Common References